Thrombospondin-1 (TSP-1) regulates endothelial cell phenotype during the tissue remodeling that is associated with angiogenesis, wound healing and neoplasia. The importance of suppression of angiogenesis by TSP-1 is underscored by the observation that TSP-1-null mice exhibit increased tumor growth and that TSP-1-based therapeutics are currently in clinical trials for the inhibition of angiogenesis. The proposed studies focus on the following areas.
Specific Aim 1. To determine the effectiveness of targeting tumor endothelial cells and tumor cells with 3TSR and TRAIL receptor agonist antibodies in preclinical mouse models. Others and we have found that the three type 1 repeats of TSP-1 (3TSR) and TNF-Related Apoptosis Inducing Ligand (TRAIL) can induce apoptosis of various tumor cells, including colon carcinomas, through the induction of endothelial cell apoptosis and tumor cell apoptosis, respectively. However, neither TRAIL nor 3TSR can induce complete tumor regression. Our studies have demonstrated that 3TSR can up- regulate death receptor (DR4 and DR5) in primary human dermal microvascular endothelial cells (HDMEC) and this sensitizes these normally TRAIL resistant cells to TRAIL-induced apoptosis. Furthermore, a combination of 3TSR and a TRAIL receptor agonist antibody results in dramatic inhibition of tumor growth in a murine model of colon cancer. The goals of this aim are to (1) establish that induction of endothelial cell apoptosis in colon cancer animal models involves CD36, activation of caspase-8 and -9, and up-regulation of murine DR5 (mDR5) and (2) test the therapeutic efficacy of combinatorial approaches using 3TSR to sensitize tumor endothelial cells to TRAIL-induced apoptosis in prevention and regression/intervention therapeutic trials using subcutaneous and orthotopic models of colon cancer.
Specific Aim 2. To identify the receptors and signaling molecules that mediate the anti-angiogenic activity of TSP-1 and 3TSR. Whereas Fyn, JNK and p38 phosphorylation have been shown to be involved in TSP-1-induced endothelial cell apoptosis, the remaining components of this signal transduction pathway are unknown. We have found that CD36 associates with vascular endothelial cell growth factor receptor 2 (VEGFR2), integrins, tetraspanins and their associated signal transduction molecules. We hypothesize that the CD36/VEGFR2/integrin complexes in the endothelial cell membrane mediate 3TSR-induced apoptosis and facilitates cross-talk between pro- and anti-angiogenic signal transduction pathways. The goals of the proposed study are to determine (1) which components of the CD36/VEGFR2/integrin complexes are essential for TSP-1- or 3TSR-induced endothelial cell apoptosis, (2) whether these complexes enable endothelial cells to integrate pro- and anti-angiogenic signals in the tumor microenvironment and (3) determine how the presence of TSP-1 or 3TSR affects the structure and function of these complexes. These studies will provide key insights into the therapeutic potential of 3TSR and TRAIL combined therapy and will elucidate the molecular basis for the inhibition of angiogenesis by TSP-1.

Public Health Relevance

The proposed research is designed to develop new strategies for inhibiting tumor growth by destroying the blood vessels that supply oxygen and nutrients to them. The goal of the proposed study is to determine how proteins that the body normally uses to limit blood vessel growth work. This knowledge will be used to develop therapeutic approaches for the treatment of cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Snyderwine, Elizabeth G
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Beth Israel Deaconess Medical Center
United States
Zip Code
Russell, Samantha; Duquette, Mark; Liu, Joyce et al. (2015) Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer. FASEB J 29:576-88
Choi, Sung Hugh; Tamura, Kaoru; Khajuria, Rajiv Kumar et al. (2015) Antiangiogenic variant of TSP-1 targets tumor cells in glioblastomas. Mol Ther 23:235-43
Ndishabandi, Dorothy; Duquette, Cameron; Billah, Ghita El-Moatassim et al. (2014) Thrombospondin-1 Modulates Actin Filament Remodeling and Cell Motility in Mouse Mammary Tumor cells in Vitro. Discoveries (Craiova) 2:
Dews, Michael; Tan, Grace S; Hultine, Stacy et al. (2014) Masking epistasis between MYC and TGF-β pathways in antiangiogenesis-mediated colon cancer suppression. J Natl Cancer Inst 106:dju043
Qin, Liuliang; Zhao, Dezheng; Xu, Jianfeng et al. (2013) The vascular permeabilizing factors histamine and serotonin induce angiogenesis through TR3/Nur77 and subsequently truncate it through thrombospondin-1. Blood 121:2154-64
Shaik, Shavali; Nucera, Carmelo; Inuzuka, Hiroyuki et al. (2012) SCF(β-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. J Exp Med 209:1289-307
Lawler, Patrick R; Lawler, Jack (2012) Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect Med 2:a006627
Adams, Josephine C; Lawler, Jack (2011) The thrombospondins. Cold Spring Harb Perspect Biol 3:a009712
Nucera, Carmelo; Lawler, Jack; Parangi, Sareh (2011) BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer Res 71:2417-22
Nucera, Carmelo; Nehs, Matthew A; Nagarkatti, Sushruta S et al. (2011) Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist 16:296-309

Showing the most recent 10 out of 15 publications